7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

78,020.00

+460.76

+0.59%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Crescent Biopharma, Inc. (CBIO)

13.48 -0.59 (-4.19%)

At close: October 30 at 4:00:02 PM EDT

13.48 0.00 (0.00%)

After hours: October 30 at 4:00:08 PM EDT

Trade CBIO on Coinbase

Loading Chart for CBIO

Chart Range Bar

Interval:

In partnership with ChartIQ

Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001

Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma to Present at September Investor Conferences

Crescent Biopharma to Present at September Investor Conferences

Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma: Q4 Earnings Snapshot

Crescent Biopharma: Q4 Earnings Snapshot

Crescent and Kelun-Biotech swap cancer asset rights in double deal

Crescent and Kelun-Biotech swap cancer asset rights in double deal

Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio

Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio

Mobilize your Website

View Site in Mobile | Classic

Share by: